Abstract
Background: The MAVORIC phase 3, randomized trial, compared safety and efficacy of mogamulizumab (Moga) with vorinostat (Vori) in patients (pts) with relapsed/refractory mycosis fungoides (MF) or Sézary syndrome (SS). Among Moga-treated pts, global overall response rate (ORR) was 28% (52/186), with median duration of response (DOR) of 14.1 months (mo). This analysis assessed the clinical and demographic characteristics of MAVORIC cohorts with varying ORR durations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
